Implanted monitor accurately detects heart rhythm disturbances

February 17, 2010

(PhysOrg.com) -- Doctors soon may be able to more accurately monitor heart rhythm disturbances and gauge the severity of atrial fibrillation (AF) with a new algorithm used in the Reveal XT leadless implantable heart monitor, according to research reported in Circulation: Arrhythmia and Electrophysiology, a journal of the American Heart Association.

“Patients with atrial fibrillation may be at significant risk for severe cardiovascular events due to the presence of the ,” said the study’s lead author, Gerhard Hindricks, M.D., Ph.D., who is also a professor at the Center of the University of Leipzig in Germany.
Detecting AF — and adequately treating it — is crucial, Hindricks said, because patients often don’t have symptoms.

Some 2.2 million Americans have AF, in which the heart’s two upper chambers - the atria - quiver instead of beating effectively. Blood isn’t completely pumped out of them, so it may pool and clot, raising the risk of stroke. Roughly one in seven strokes occur in people with AF, according to American Heart Association statistics.

In the study, 247 patients suspected of having sporadic irregular heart rhythms were implanted with the Reveal XT monitor and outfitted with a Holter monitor. This allowed researchers to compare heartbeats recorded by each monitor for the 46-hour study period. The Reveal XT monitor, which is the size of a camera’s memory stick, was inserted just under a patient’s skin using local anesthesia. A Holter monitor is commonly used to detect AF. It has wires attached to the chest and is worn on the waist much like a music player.

The study enrolled patients from 24 medical centers, mainly in Europe and Canada. Patients had an average age of 57, and 67 percent were men. About 10 percent had a history of stroke or transient ischemic attack.

The researchers found that the new computation method with the Reveal monitor was highly sensitive, correctly detecting AF in 96.1 percent of all patients with AF.

“Even with repetitive, seven-day Holter monitoring, may not be detected in a significant number of patients,” said Hindricks. He expects the new device to be used as a way to assess treatment of patients. “Only continuous long-term rhythm monitoring will be able to precisely define the rhythm outcome or efficacy of such treatment,” he said.

Hindricks added that further studies are needed to determine the longer-term accuracy of the Reveal monitor. “The device has a limited data storage capacity (49.5 minutes of data), and this may be a limitation during longer follow-up periods - especially since the presence of false positive episodes may exceed the storage capacity in some patients. Thus, long-term performance and validation studies are needed to find the optimal way of handling the device.”

Related Stories

Recommended for you

Two Group A Streptococcus genes linked to 'flesh-eating' bacterial infections

September 22, 2017
Group A Streptococcus bacteria cause a variety of illnesses that range from mild nuisances like strep throat to life-threatening conditions including pneumonia, toxic shock syndrome and the flesh-eating disease formally known ...

Ecosystem approach makes urinary tract infection more treatable

September 22, 2017
The biological term 'ecosystem' is not usually associated with urinary tract infections, but this should change according to Wageningen scientists.

Residents: Frontline defenders against antibiotic resistance?

September 22, 2017
Antibiotic resistance continues to grow around the world, with sometimes disastrous results. Some strains of bacteria no longer respond to any currently available antibiotic, making death by infections that were once easily ...

Individualized diets for irritable bowel syndrome better than placebo

September 21, 2017
Patients with irritable bowel syndrome who follow individualized diets based on food sensitivity testing experience fewer symptoms, say Yale researchers. Their study is among the first to provide scientific evidence for this ...

Superbug's spread to Vietnam threatens malaria control

September 21, 2017
A highly drug resistant malaria 'superbug' from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine—Vietnam's national first-line malaria treatment, ...

A dose of 'wait-and-see' reduces unnecessary antibiotic use

September 21, 2017
Asking patients to take a 'wait-and-see' approach before having their antibiotic prescriptions filled significantly reduces unnecessary use, a University of Queensland study has shown.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.